Is It Safe to Take Lisinopril and Metformin Together?

Yes, lisinopril and metformin are generally safe to use together, and this combination is routinely prescribed to millions of patients with concurrent hypertension and type 2 diabetes. However, this pairing requires careful monitoring of kidney function and blood glucose levels, as both drugs can affect renal clearance and metabolic status. Patients on this combination should have regular laboratory monitoring and should always verify the specific dosages and their individual health status with their pharmacist or physician.

Prevalence of This Combination in Clinical Practice

The concurrent use of lisinopril and metformin is extremely common in real-world clinical settings. Approximately 30% of patients with type 2 diabetes also have hypertension, and ACE inhibitors like lisinopril are a preferred antihypertensive class in this population due to their renal protective effects. According to data from the National Health and Nutrition Examination Survey (NHANES), roughly 12–15 million Americans are on ACE inhibitors for hypertension management, and a substantial proportion of these patients also take metformin. The American Diabetes Association explicitly recommends ACE inhibitors as first-line therapy for hypertensive patients with diabetes, making this combination evidence-based standard care.

What the FDA Says

The FDA labeling for both lisinopril and metformin does not flag a direct contraindication or serious interaction between these two drugs. However, both agents carry important class-level warnings that apply when used together.

Lisinopril FDA labeling (per FDA drug label via OpenFDA) includes warnings for:

• Hyperkalemia risk, particularly in patients with renal impairment or concurrent use of potassium-sparing agents
• Angioedema (rare but serious)
• Hypotension, especially with concurrent diuretic use
• Cough (a common ACE inhibitor side effect occurring in 10–20% of patients)
• Renal function deterioration in patients with baseline renal disease

Metformin FDA labeling (per FDA drug label via OpenFDA) includes warnings for:

• Lactic acidosis risk (though rare, occurring at a rate of approximately 4.3 cases per 100,000 patient-years in the US), particularly with renal impairment
• Renal function monitoring requirement
• Contrast dye interaction (metformin should be held around imaging procedures)
• Gastrointestinal side effects

The critical overlap in FDA warnings centers on renal function. Both drugs are affected by, and can affect, kidney clearance. There are no published FDA adverse event reports specifically linking lisinopril and metformin as a dangerous pair, and no recall or safety communication has targeted this combination.

How This Interaction Works: Pharmacological Mechanisms

Understanding why monitoring is necessary requires examining how these two drugs are processed in the body and how they affect kidney function.

Renal Clearance and the Kidneys as the Common Site of Action

Metformin is a polar, hydrophilic molecule that is not metabolized by the liver. Instead, 90% of metformin is excreted unchanged by the kidneys through glomerular filtration and active tubular secretion. The remaining 10% is cleared through unknown mechanisms. This makes metformin extremely dependent on adequate renal function.

Lisinopril is an ACE inhibitor that is not metabolized and is eliminated almost entirely by renal clearance. Like metformin, lisinopril depends on kidney function for clearance. When lisinopril is given, it works by inhibiting the conversion of angiotensin I to angiotensin II, which leads to vasodilation and reduced glomerular filtration pressure.

Here is where the potential concern emerges: ACE inhibitors like lisinopril can actually reduce the glomerular filtration rate (GFR), particularly in the short term when therapy is initiated or when doses are increased. In patients with baseline chronic kidney disease, renal artery stenosis, or those who are volume-depleted, lisinopril can cause a measurable decline in kidney function. If kidney function declines, metformin clearance also declines, which can lead to drug accumulation and increased lactic acidosis risk.

Hyperkalemia Risk

Both drugs can contribute to elevated serum potassium (hyperkalemia), though through different mechanisms. Lisinopril reduces angiotensin II, which normally promotes sodium reabsorption and potassium excretion in the distal tubule. Blocking this pathway increases potassium retention. Metformin does not directly cause hyperkalemia, but in the setting of declining renal function, patients taking lisinopril become more prone to potassium accumulation.

Blood Pressure and Blood Glucose Dynamics

Lisinopril lowers blood pressure through vasodilation. In some patients, this can reduce renal perfusion pressure and GFR. Additionally, ACE inhibitors can improve insulin sensitivity in some patients with diabetes, potentially enhancing the glucose-lowering effect of metformin. This is generally beneficial but requires awareness to prevent hypoglycemia in vulnerable patients.

Who Is Most at Risk

Not all patients on this combination face the same risk. The following populations require heightened monitoring:

• Patients with baseline renal impairment (eGFR <60 mL/min/1.73m²): Lisinopril can further reduce GFR in these patients, and metformin is contraindicated or requires dose reduction at eGFR <30. The interaction risk climbs steeply in this group.
• Elderly patients (age >65): Aging is associated with declining renal function, reduced drug clearance, and increased volume depletion risk. Medicare data shows that ~40% of patients over 65 have an eGFR <60.
• Dehydration or acute illness: Patients who become volume-depleted (from vomiting, diarrhea, or prolonged fasting) face a sharp increase in lactic acidosis risk when on metformin, especially if lisinopril-induced hypotension compounds the problem.
• Concurrent use of NSAIDs or diuretics: These agents reduce renal blood flow and compound the GFR-lowering effect of lisinopril. A patient on lisinopril + metformin + an NSAID for arthritis is at substantially higher risk.
• Patients with heart failure: Those with reduced ejection fraction who are on lisinopril for cardioprotection may experience worsening renal function if metformin is added without dose adjustment.
• Contrast dye exposure: Patients undergoing cardiac catheterization or CT imaging with iodinated contrast while on this combination face acute kidney injury risk, which can precipitate metformin-associated lactic acidosis.

Clinical Scenario 1: Stable Management

A 62-year-old woman with a 10-year history of type 2 diabetes and hypertension presents to her primary care physician with a blood pressure of 148/92 mmHg. Her current medications include metformin 1,000 mg twice daily and atorvastatin 20 mg daily. Her serum creatinine is 0.9 mg/dL (eGFR ~75 mL/min/1.73m² based on MDRD equation), and her potassium is 4.2 mEq/L. Her hemoglobin A1C is 7.1%.

The physician starts lisinopril 10 mg once daily. At a follow-up visit 4 weeks later, her blood pressure is 138/88 mmHg. Laboratory work shows serum creatinine of 0.95 mg/dL (eGFR ~70), potassium 4.4 mEq/L, and fasting glucose 115 mg/dL. No lactic acidosis symptoms are present. This scenario represents appropriate use of the combination: the patient has baseline normal renal function, lisinopril was initiated at a standard dose, follow-up labs were obtained, and no concerning changes were detected. The slight increase in creatinine and potassium are within expected ACE inhibitor initiation effects and do not require immediate intervention, though continued monitoring is warranted.

Clinical Scenario 2: High-Risk Situation Requiring Intervention

A 74-year-old man with a 15-year history of type 2 diabetes, hypertension, and stage 3b chronic kidney disease (eGFR 38 mL/min/1.73m²) is on metformin 500 mg twice daily (reduced from higher doses due to renal impairment) and lisinopril 20 mg daily for hypertension and cardioprotection. He develops severe gastroenteritis with vomiting and diarrhea lasting 48 hours. He becomes severely dehydrated and develops acute kidney injury; his serum creatinine rises from 1.8 mg/dL to 2.4 mg/dL, and his eGFR drops to 25 mL/min/1.73m². His potassium rises to 5.6 mEq/L. He develops malaise, shortness of breath, and mild confusion.

In this scenario, the combination of lisinopril and metformin, previously at baseline acceptable risk, has become dangerous. The acute kidney injury from dehydration has dramatically reduced drug clearance for both agents. Metformin accumulates and increases lactic acidosis risk (his confusion and malaise may be early signs). His elevated potassium, worsened by lisinopril's renal effects in the setting of acute renal failure, requires urgent intervention. The appropriate management here includes: immediate discontinuation of both lisinopril and metformin, aggressive IV hydration, hospital admission, frequent laboratory monitoring (basic metabolic panel and lactate level), and holding these medications until renal function stabilizes. This scenario illustrates why patient education about holding medications during acute illness is critical.

What to Do: Management Guidance for Patients

Before Starting This Combination

• Ensure your doctor and pharmacist know your complete medication list, including OTC drugs and supplements.
• Have your baseline kidney function tested (serum creatinine and eGFR) and your potassium level checked.
• Disclose any history of kidney disease, heart failure, or recurrent dehydration.
• Ask your doctor whether you need to hold metformin around any upcoming contrast dye procedures or surgeries.

While Taking This Combination

• Follow your doctor's schedule for lab monitoring. Most guidelines recommend checking kidney function and potassium 1–2 weeks after lisinopril initiation or dose change, then every 6–12 months if stable.
• Stay well-hydrated, especially in hot weather or during exercise.
• Avoid NSAIDs (ibuprofen, naproxen) unless specifically approved by your doctor; use acetaminophen for pain instead.
• Do not abruptly stop either medication without consulting your doctor.
• Monitor your blood glucose at home if you have a glucose meter; report any unusual low blood sugar episodes to your doctor.
• Be aware of the side effects: ACE inhibitors commonly cause a dry cough; metformin often causes mild GI upset, which usually improves with time.

During Acute Illness or Dehydration

• If you have severe vomiting, diarrhea, or reduced oral intake lasting more than a few hours, contact your doctor or pharmacist about whether to temporarily hold metformin.
• Lisinopril may also need to be held during severe dehydration to prevent hypotension and worsening renal function.
• Do not make these decisions alone; speak with your healthcare provider.

When to Call Your Doctor or Pharmacist

Seek immediate medical attention if you experience:

• Shortness of breath, chest pain, or severe dizziness: These may indicate hyperkalemia, lactic acidosis, or severe hypotension.
• Swelling of the face, lips, tongue, or throat (angioedema): A rare but serious ACE inhibitor side effect requiring immediate emergency care.
• Persistent severe muscle pain, weakness, or numbness: Possible signs of lactic acidosis.
• Confusion, difficulty concentrating, or unusual fatigue: Could indicate severe hyperkalemia or lactic acidosis.
• Severe persistent cough: Common with ACE inhibitors; your doctor may need to switch you to an alternative agent.
• Persistent fever, severe infection, or signs of sepsis: Acute illness warrants lab work to assess kidney function and drug safety.
• Severe or persistent nausea, vomiting, or diarrhea: Can lead to dehydration and altered drug clearance.

Contact your doctor (not necessarily emergency care) if you notice:

• New or worsening erectile dysfunction (can occur with some antihypertensives)
• Unexplained weight gain or swelling in legs or feet (possible volume overload)
• Persistent dry cough that is bothersome (may need to switch ACE inhibitor or class)
• Frequent low blood sugar episodes (may need to adjust metformin dose)

Drug Interaction Cross-Check: Related Combinations

If you are on lisinopril and metformin, ask your pharmacist about these related interactions:

• Other ACE inhibitors and metformin — similar risk profile to lisinopril
• Metformin and iodinated contrast dye — requires holding metformin before imaging
• Lisinopril and NSAIDs — combined renal risk

Key Takeaways

• Lisinopril and metformin are safe to use together in most patients and represent standard evidence-based care for those with concurrent hypertension and type 2 diabetes, with no FDA-flagged contraindication between them.
• The primary concern is renal function: both drugs depend on kidney clearance, and ACE inhibitors can reduce kidney function, potentially causing metformin accumulation and increasing lactic acidosis risk, particularly in elderly patients, those with baseline renal disease, or during dehydration.
• Baseline and periodic monitoring of serum creatinine, eGFR, and potassium is essential; follow-up labs should be obtained 1–2 weeks after lisinopril initiation or dose increase, then every 6–12 months if stable.
• Patients at highest risk include those over age 65, those with eGFR <60, those taking NSAIDs or diuretics concurrently, and those with heart failure or recurrent dehydration.
• During acute illness with vomiting, diarrhea, or severe dehydration, contact your doctor about temporarily holding metformin and possibly lisinopril to prevent acute kidney injury and lactic acidosis.

Sources

• FDA Drug Labeling for Lisinopril via OpenFDA: open.fda.gov
• FDA Drug Labeling for Metformin via OpenFDA: open.fda.gov
• National Kidney Foundation: KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. kdigo.org
• American Diabetes Association Standards of Care in Diabetes. care.diabetesjournals.org
• NIH National Library of Medicine: Metformin-Associated Lactic Acidosis (MALA) in the Setting of Acute Kidney Injury. PubMed Database: pubmed.ncbi.nlm.nih.gov
• United States Renal Data System (USRDS) Annual Data Report. usrds.org
• National Health and Nutrition Examination Survey (NHANES) Data: CDC/NCHS. cdc.gov/nchs/nhanes

This post provides clinically grounded information based on current FDA labeling and guidelines, but it is not a substitute for professional medical advice. Your doctor and pharmacist are the best sources for guidance on your individual medications. If you take lisinopril, metformin, or both, use checkdruginteractions.com to verify your entire medication list against our FDA-powered interaction database. Enter all of your prescription medications, over-the-counter drugs, and supplements to receive a comprehensive safety report tailored to your unique health profile. Always consult your pharmacist before starting, stopping, or changing any medication.